ImmunityBio Inc.

3.13
-0.23 (-6.85%)
At close: Mar 28, 2025, 3:59 PM
3.06
-2.08%
After-hours: Mar 28, 2025, 06:57 PM EDT
-6.85%
Bid 3.06
Market Cap 2.67B
Revenue (ttm) 17.16M
Net Income (ttm) -481.38M
EPS (ttm) -0.62
PE Ratio (ttm) -5.04
Forward PE -7.33
Analyst Buy
Ask 3.07
Volume 8,244,153
Avg. Volume (20D) 6,117,848
Open 3.41
Previous Close 3.36
Day's Range 3.02 - 3.47
52-Week Range 2.28 - 10.53
Beta -0.18

About IBRX

ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of...

Industry Biotechnology
Sector Healthcare
IPO Date Jul 28, 2015
Employees 680
Stock Exchange NASDAQ
Ticker Symbol IBRX
Full Company Profile

Analyst Forecast

According to 5 analyst ratings, the average rating for IBRX stock is "Buy." The 12-month stock price forecast is $8, which is an increase of 156.00% from the latest price.

Stock Forecasts

Next Earnings Release

ImmunityBio Inc. is scheduled to release its earnings on May 8, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago
-13.37%
ImmunityBio shares are trading lower after the com... Unlock content with Pro Subscription
4 weeks ago
+15.03%
ImmuniyBio shares are trading higher after the company announced it received FDA RMAT Designation for ANKTIVA(R) and CAR-NK.